BioCentury | Sep 10, 2019
Financial News

Pharvaris raises $66M series B for clinical development of oral HAE therapy

...Partners, LSP and Idinvest Partners. Pharvaris' team, which developed HAE drug Firazyr icatibant while at Jerini AG...
...Pharmaceutical Co. Ltd. (Tokyo:4502) markets Firazyr as a self-administered drug for acute attacks; Shire acquired Jerini...
...and venBio's Richard Gaster have joined Pharvaris' board. Mary Romeo, Assistant Editor Firazyr, icatibant (JE049) PHA121 Bain Capital Foresite Capital Idinvest Partners Jerini AG Kurma...
BioCentury | May 31, 2018
Emerging Company Profile

Oral route for HAE

...they’ve been asking for. Pharvaris B.V. brings together team members responsible for developing Firazyr at Jerini AG...
...of the disease,” said CSO and COO Jochen Knolle, who developed Firazyr while CSO at Jerini...
...new molecule that was better than icatibant,” said CEO Berndt Modig, who was CFO at Jerini...
BioCentury | Jan 12, 2018
Company News

Shire to split neuro and rare disease businesses

...assets that address different, complimentary segments of the market. The pharma used three acquisitions -- Jerini AG...
...18, 2016 ). Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Neurology Elizabeth S. Eaton Adderall XR Advate Adynovate Elvanse Obizur Recombinate Baxalta Inc. Dyax Corp. Jerini AG Shire...
BioCentury | Jan 9, 2018
Company News

Shire splits neuro and rare disease businesses

...assets that address different, complimentary segments of the market. The pharma used three acquisitions -- Jerini AG...
...to 3,708.50p in London and gained $1.69 to $150.79 in New York. Elizabeth S. Eaton Adderall XR Elvanse Dyax Corp. Jerini AG Shire...
BioCentury | Jan 18, 2016
Strategy

Shire's serial story

...portfolio of drugs to treat different segments of hereditary angioedema (HAE). The 2008 acquisition of Jerini AG...
BioCentury | Nov 9, 2015
Finance

HAE maker

...testing this quarter to prevent HAE attacks. Shire entered HAE in 2008 when it bought Jerini AG...
BioCentury | Mar 3, 2014
Clinical News

Firazyr icatibant regulatory update

...acute attacks of hereditary angioedema (HAE) in adults. Shire gained Firazyr through its acquisition of Jerini AG...
BioCentury | Apr 1, 2013
Strategy

Shire sees opportunity

...said. Shire gained an initial basket of ophthalmic assets via its July 2008 acquisition of Jerini AG...
...receptor ( BDKRB2 ; B2R ) antagonist marketed for hereditary angioedema (HAE). Jerini's U.S. subsidiary, Jerini...
...associated with dry AMD (see BioCentury, Oct. 20, 2008). Less than a year after buying Jerini...
BioCentury | Mar 19, 2012
Clinical News

Firazyr icatibant regulatory update

...indication last year (see BioCentury, Aug. 29, 2011). Shire gained Firazyr through its acquisition of Jerini AG...
BioCentury | Aug 29, 2011
Clinical News

Firazyr icatibant regulatory update

...extension approved this year to allow for self-administration. Shire gained Firazyr through its acquisition of Jerini AG...
Items per page:
1 - 10 of 226
BioCentury | Sep 10, 2019
Financial News

Pharvaris raises $66M series B for clinical development of oral HAE therapy

...Partners, LSP and Idinvest Partners. Pharvaris' team, which developed HAE drug Firazyr icatibant while at Jerini AG...
...Pharmaceutical Co. Ltd. (Tokyo:4502) markets Firazyr as a self-administered drug for acute attacks; Shire acquired Jerini...
...and venBio's Richard Gaster have joined Pharvaris' board. Mary Romeo, Assistant Editor Firazyr, icatibant (JE049) PHA121 Bain Capital Foresite Capital Idinvest Partners Jerini AG Kurma...
BioCentury | May 31, 2018
Emerging Company Profile

Oral route for HAE

...they’ve been asking for. Pharvaris B.V. brings together team members responsible for developing Firazyr at Jerini AG...
...of the disease,” said CSO and COO Jochen Knolle, who developed Firazyr while CSO at Jerini...
...new molecule that was better than icatibant,” said CEO Berndt Modig, who was CFO at Jerini...
BioCentury | Jan 12, 2018
Company News

Shire to split neuro and rare disease businesses

...assets that address different, complimentary segments of the market. The pharma used three acquisitions -- Jerini AG...
...18, 2016 ). Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Neurology Elizabeth S. Eaton Adderall XR Advate Adynovate Elvanse Obizur Recombinate Baxalta Inc. Dyax Corp. Jerini AG Shire...
BioCentury | Jan 9, 2018
Company News

Shire splits neuro and rare disease businesses

...assets that address different, complimentary segments of the market. The pharma used three acquisitions -- Jerini AG...
...to 3,708.50p in London and gained $1.69 to $150.79 in New York. Elizabeth S. Eaton Adderall XR Elvanse Dyax Corp. Jerini AG Shire...
BioCentury | Jan 18, 2016
Strategy

Shire's serial story

...portfolio of drugs to treat different segments of hereditary angioedema (HAE). The 2008 acquisition of Jerini AG...
BioCentury | Nov 9, 2015
Finance

HAE maker

...testing this quarter to prevent HAE attacks. Shire entered HAE in 2008 when it bought Jerini AG...
BioCentury | Mar 3, 2014
Clinical News

Firazyr icatibant regulatory update

...acute attacks of hereditary angioedema (HAE) in adults. Shire gained Firazyr through its acquisition of Jerini AG...
BioCentury | Apr 1, 2013
Strategy

Shire sees opportunity

...said. Shire gained an initial basket of ophthalmic assets via its July 2008 acquisition of Jerini AG...
...receptor ( BDKRB2 ; B2R ) antagonist marketed for hereditary angioedema (HAE). Jerini's U.S. subsidiary, Jerini...
...associated with dry AMD (see BioCentury, Oct. 20, 2008). Less than a year after buying Jerini...
BioCentury | Mar 19, 2012
Clinical News

Firazyr icatibant regulatory update

...indication last year (see BioCentury, Aug. 29, 2011). Shire gained Firazyr through its acquisition of Jerini AG...
BioCentury | Aug 29, 2011
Clinical News

Firazyr icatibant regulatory update

...extension approved this year to allow for self-administration. Shire gained Firazyr through its acquisition of Jerini AG...
Items per page:
1 - 10 of 226